

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. SERIAL NO.

: 10/566,625

APPLICANTS

: Klaus, et al.

FILING DATE

: 2 November 2006

GROUP ART UNIT

: 1645

EXAMINER

: Oluwatosin A. Ogunbiyi

DOCKET NO.

: FP0617 US

TITLE

: INHIBITORS OF 2-OXOGLUTARATE DIOXYGENASE AS GAMMA

GLOBIN INDUCERS

Commissioner for Patents

PO Box 1450

Alexandria VA 22313-1450

TRANSMITTAL

The following items accompany this Transmittal:

- 1. Return Receipt Postcard
- 2. Supplemental Information Disclosure Statement (2pgs)
- 3. PTO/SB/08a (1pg)
- 4. PTO/SB/08b (3pgs)
- 5. References (29 1 Int'l App, 28 Articles)

Applicants claim small entity status under 37 C.F.R. 1.27.

The Commissioner is hereby authorized to charge any necessary fees to Deposit Account No. 50-0811, referencing Docket No. FP0617 US.

Please call Applicants' representative at 650.866.7265 with any questions regarding this communication or the above-identified application.

Respectfully submitted,

Date: 15 Sept 2008

By:

Christopher Turner, Ph.D.

Reg. No. 45,167

FibroGen, Inc.

225 Gateway Boulevard

South San Francisco CA 94080

Main: 650.866.7200 Direct: 650.866.7265 Facsimile: 650.866.7292 cturner@fibrogen.com

Certificate of mailing or transmission under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 15 September 2008.

Name:

Michael Moores

Signature



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. SERIAL NO.

: 10/566,625

APPLICANTS

: Klaus, et al.

: 2 November 2006

FILING DATE
GROUP ART UNIT

: 1645

EXAMINER

: Oluwatosin A. Ogunbiyi

DOCKET NO.

: FP0617 US

TITLE

: INHIBITORS OF 2-OXOGLUTARATE DIOXYGENASE AS GAMMA

GLOBIN INDUCERS

Commissioner for Patents

PO Box 1450

Alexandria VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(b)

Sir:

Pursuant to 37 C.F.R. 1.56, 1.97, and 1.98, Applicants wish to call to the attention of the Examiner the enclosed forms PTO/SB08a and PTO/SB08b. Applicants reserve the right to antedate any reference in accordance with standard procedure.

The Examiner's attention is directed to copending application number 11/348294 (US Application Publication No. 2007/0185045), naming Peter J. Ratcliffe as inventor(s) and filed on 6 February 2006. The copending application and the documents of record in the copending application are listed on the enclosed forms PTO/SB08a and PTO/SB08b. Since the copending application is available in the Patent Application Information Retrieval (PAIR) system, a copy of the copending application is not required to be submitted. By citation to the copending application, confidentiality is not waived and the Office is requested to maintain the confidentiality of the copending application under 35 U.S.C. § 122.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the present application. In addition, this submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI or other report included on the attached list may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings. Applicants respectfully request that the

Certificate of mailing or transmission under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 15 September 2008.

Name:	Michael	Moores

Signature:

cited documents be considered by the Examiner and that an initialed copy of the enclosed forms PTO/SB08a and PTO/SB08b be returned to Applicants.

Applicants claim small entity status under 37 C.F.R. 1.27.

The Commissioner is hereby authorized to charge the total of the fee due in the Supplemental Information Disclosure Statement to Deposit Account No. 50-0811, referencing Docket No. FP0617 US.

Please call Applicants' representative at 650.866.7265 with any questions regarding this communication or the above-identified application.

By:

Respectfully submitted,

Date: 15 Sept 2008

Christopher Turner, Ph.D.

Reg. No. 45,167

FibroGen, Inc. 225 Gateway Boulevard South San Francisco CA 94080

Main: 650.866.7200 Direct: 650.866.7265 Facsimile: 650.866.7292 ctmmer@fibrogen.com